



Therapeutic Interchange for Insulin

Ordered As	Substitute
Rapid-acting	
<i>insulin aspart (Novolog)</i> <i>Insulin aspart (Fiasp)</i> <i>insulin glulisine (Apidra)</i> <i>insulin lispro (Admelog)</i>	<i>insulin lispro vial (Humalog)</i> on a 1:1 unit:unit basis
Short-acting	
<i>regular insulin (Novolin R)</i> CONCENTRATED <i>regular insulin (Humulin R U-500)</i>	<i>regular insulin (Humulin R)</i> on a 1:1 unit:unit basis Only to be used for refilling patient’s home insulin pump, otherwise must be converted to basal/bolus If not for insulin pump, RPh will: <ol style="list-style-type: none"> 1. Confirm home U-500 dose 2. Obtain answers to the following questions: <ol style="list-style-type: none"> a. Has the patient experienced hypoglycemia event recently on home dose? <ol style="list-style-type: none"> i. YES/NO b. Has the patient had compliance issues with home U-500 insulin regimen? <ol style="list-style-type: none"> i. YES/NO 3. If the answer is NO (#2.a.i) and NO (#2.b.i) – use conversion of 50% of U-500 insulin to basal and bolus regimen. Also, calculate the dose that 0.6 units/kg would provide to verify that the patient’s dose is a realistic dose. <ol style="list-style-type: none"> a. EXAMPLE: if patient is on total of 300 units of U-500 insulin at home <ol style="list-style-type: none"> i. Total calculated conversion = $300 \times 0.5 = 150$ units ii. Calculated Basal (Lantus dose): 75 units at bedtime (1/2 of 150 units) iii. Calculated Mealtime Bolus (Humalog dose): 75 units/3 then 3 times daily = 25 units TID with meals iv. Add comment that patient was on U-500 insulin at home 4. If the answer is YES to either question – contact prescribing physician and recommend a starting dose of 0.6 units/kg divided half basal and bolus <ol style="list-style-type: none"> a. EXAMPLE: Patient weight is 150 kg.

	<p>Calculated dose is 0.6 units/kg = 90 units TOTAL</p> <p>i. Calculated Basal (Lantus dose) = 45 units (1/2 of 90 total units)</p> <p>ii. Calculated Mealtime Bolus (Humalog dose): 45 units/3 then 3 times daily = 15 units TID with meals</p> <p>5. If a patient is unable to answer assessment questions, select between lower of doses (0.6 units/kg and 50% of home dose)</p> <p>6. If a patient is NPO for a procedure, contact physician and recommend only basal dose (based on formula above) with sliding scale</p> <p>7. Pharmacists put in an Ad hoc note to document</p> <p>8. If prescriber needs assistance to convert patient back to home U-500 regimen on discharge, they can request this from pharmacist</p>
Intermediate-acting	
<i>isophane insulin (Novolin N)</i>	<i>isophane insulin (Humulin N)</i> on a 1:1 unit:unit basis
Long-acting	
<i>insulin detemir (Levemir)</i>	Insulin glargine (Lantus) Human 100 units/10 mL vial on 1:1 unit:unit basis** A lower dose may be needed
<i>insulin degludec (Tresiba 200 U/mL and 100 U/mL FlexTouch Pens)</i>	Insulin glargine (Lantus) Human 100 units/10 mL vial **Decrease dose by 20% when transitioning to insulin glargine If converting from Tresiba <80 units/day, administer once daily If converting from Tresiba >80 units/day, divide and administer twice daily
<i>Insulin glargine (Toujeo 300 U/mL)</i>	Insulin glargine (Lantus) Human 100 units/10 mL vial **Use 80% of the dose of Toujeo (eg, 20% reduction)
<i>Insulin glargine (Basaglar)</i>	Insulin glargine (Lantus) Human 100 units/10 mL vial on 1:1 unit:unit basis
Insulin Mixtures	
<i>insulin aspart protamine 70% and insulin aspart 30% (Novolog 70/30)</i>	Insulin lispro protamine 75% and insulin lispro 25% (Humalog 75/25) on a 1:1 unit:unit basis
<i>isophane insulin 70% and regular insulin 30% (Novolin 70/30)</i>	isophane insulin 70% and regular insulin 30% (Humulin 70/30) on a 1:1 unit:unit basis

*Conversion FROM once-daily Lantus TO once-daily Toujeo: May be substituted on an equivalent unit-per-unit basis

***Insulin glargine syringes are drawn up in IV room from vials to specific unit dose*

References

1. Clinical Resource, **How to Switch Insulin Products. Pharmacist's Letter/Prescriber's Letter.** August 2019.
2. Tresiba (insulin degludec) injection package insert. Plainsboro, NJ: Novo Nordisk Inc.; 2015 Sep. <http://www.novo-pi.com/tresiba.pdf>.
3. Lantus (insulin glargine [rDNA origin] injection) solution for subcutaneous injection package insert. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2015 July. <http://products.sanofi.us/lantus/lantus.html>.